STELLAR-303: A phase 3 study of XL092 in combination with atezolizumab versus regorafenib in patients with previously treated metastatic colorectal cancer (mCRC)

by on 22 de gener de 2024 with No hi ha comentaris
  • Hecht, J. R., Tabernero, J., Parikh, A. R., Wang, Y. J., Wang, Z., Schwickart, M., . . . Saeed, A. (2023). STELLAR-303: A phase 3 study of XL092 in combination with atezolizumab versus regorafenib in patients with previously treated metastatic colorectal cancer (mCRC). Journal of Clinical Oncology, 41, TPS267-TPS267. https://doi.org/10.1200/JCO.2023.41.4_suppl.TPS267

Deixa un comentari

L'adreça electrònica no es publicarà. Els camps necessaris estan marcats amb *